GlassScriptPhysician profile
Ashish B Patel
NPI 1104023977
$5,395.77
in general payments reported to CMS, 2019-2025
36 companies · $718 in 2025
The $718 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,817 · 2020: $625 · 2021: $649 · 2022: $410 · 2023: $537 · 2024: $640 · 2025: $718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,701 · Education: $180 · Travel and Lodging: $13.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,701.40 |
| Education | $180.19 |
| Travel and Lodging | $13.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,737.28 | 2019-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Mylan Specialty L.P. | $461.35 | 2019-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $417.18 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $287.25 | 2019-2025 | Airsupra, Breztri |
| Verona Pharma, INC. | $246.09 | 2025 | Ohtuvayre |
| La Jolla Pharmaceutical Company | $228.90 | 2019-2023 | Giapreza |
| Abbott Laboratories | $180.19 | 2024 | Ensite |
| Lilly USA, LLC | $152.15 | 2024-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $150.99 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $143.95 | 2019-2025 | Opsumit, Uptravi |
| Insmed, INC. | $136.76 | 2019-2025 | Arikayce |
| Advanced Respiratory, INC | $136.33 | 2019 | |
| Boston Scientific Corporation | $123.78 | 2021 | |
| Idorsia Pharmaceuticals US INC | $120.52 | 2023 | Quviviq |
| Grifols USA, LLC | $116.59 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $81.79 | 2019-2020 | |
| Inspire Medical Systems, INC. | $64.18 | 2024-2025 | Inspire |
| Mallinckrodt Enterprises LLC | $59.33 | 2019 | |
| Pfizer INC. | $58.48 | 2019 | |
| Allergan, INC. | $49.42 | 2019 | |
| Paratek Pharmaceuticals, INC. | $45.73 | 2020-2025 | Nuzyra |
| Regeneron Healthcare Solutions, INC. | $42.25 | 2021 | |
| Covidien LP | $35.97 | 2019 | |
| Circassia INC. | $35.71 | 2019-2020 | |
| Liquidia Technologies, INC. | $29.84 | 2025 | Yutrepia |
| Shionogi INC | $29.84 | 2022 | |
| Harmony Biosciences LLC | $29.72 | 2021 | |
| Viatris Specialty LLC | $27.23 | 2025 | Yupelri |
| Alexion Pharmaceuticals, INC. | $26.60 | 2021 | |
| Pulmonx Corporation | $24.22 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Janssen Pharmaceuticals, INC | $23.17 | 2019 | |
| Genzyme Corporation | $22.83 | 2019 | |
| Optinose US, INC. | $20.00 | 2024 | |
| Nuvasive, INC. | $19.15 | 2022 | |
| Nabriva Therapeutics, Plc | $18.57 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashish Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.